TABLE 1.
Characteristics of Patients With CD Treated to Target of Clinical and Endoscopic Remission According to Histologic Results
| Variables | Patients With Persistent Histologic Activity (n = 83) | Patients With Histologic Remission (n = 132) | P |
|---|---|---|---|
| Age at enrollment (y) | 33 (24-48) | 33 (24-51) | 0.919 |
| Sex (male) | 44 (53.0) | 55 (41.7) | 0.123 |
| Smoking status | 0.885 | ||
| Never | 63 (75.9) | 100 (75.8) | — |
| Ex-smoker | 14 (16.9) | 20 (15.2) | — |
| Current smoker | 6 (7.2) | 12 (9.1) | — |
| Family history of IBD | 4 (4.8) | 11 (8.3) | 0.416 |
| Disease duration (y) | 7 (1-12) | 5 (1-14) | 0.468 |
| Early CD* | 25 (30.1) | 49 (37.1) | 0.306 |
| Age at diagnosis (y) | 1.0 | ||
| A1 (≤16) | 17 (20.5) | 26 (19.7) | — |
| A2 (17-40) | 52 (62.7) | 83 (62.9) | — |
| A3 (>40) | 14 (16.9) | 23 (17.4) | — |
| Location of disease | 0.888 | ||
| L1 (ileum) | 17 (20.5) | 31 (23.5) | — |
| L2 (colon) | 28 (33.7) | 44 (33.3) | — |
| L3 (ileocolon) | 38 (45.8) | 57 (43.2) | — |
| Behavior of disease | 0.888 | ||
| B1 (nonstricturing and nonpenetrating) | 48 (57.8) | 74 (56.1) | — |
| B2 or B3 | 35 (42.2) | 58 (43.9) | — |
| History of perianal disease | 19 (22.9) | 30 (22.7) | 1.0 |
| History of abdominal surgery | 24 (28.9) | 38 (28.8) | 1.0 |
| Prior exposure to TNF antagonists (before current therapy) | 41 (49.4) | 59 (44.7) | 0.575 |
| Number of prior biologics exposed (before current therapy) | 0.627 | ||
| 0 | 41 (49.4) | 72 (54.6) | — |
| 1 | 23 (27.7) | 29 (22.0) | — |
| ≥2 | 19 (22.9) | 31 (23.5) | — |
| Medication used for achieving remission (current therapy) | 0.724 | ||
| Nonbiologic medications† | 6 (7.2) | 12 (9.1) | — |
| TNF antagonists | 57 (68.7) | 88 (66.7) | — |
| Vedolizumab | 7 (8.4) | 16 (12.1) | — |
| Ustekinumab | 13 (15.7) | 16 (12.1) | — |
| Time taken to achieve ER (mo) | 9 (6-20) | 11 (7-20) | 0.175 |
Variables are expressed as median (interquartile range) or n (%).
*Definition of early CD: disease duration <2 years.
†Nonbiologic medications included antimetabolites, steroids, 5-aminosalicylic acids, or no treatment.
ER indicates endoscopic remission.